David Arroyo
YOU?
Author Swipe
Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode Open
Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, gui…
View article: Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia
Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia Open
Key Points Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is frequently downtitrated or discontinued after a hyperkalemia episode. Reducing RAASi therapy after a hyperkalemia episode is associated with increased risk of hos…
View article: Tubular biomarkers and histology in lupus nephritis
Tubular biomarkers and histology in lupus nephritis Open
Introduction The relevance of tubulo‐interstitial involvement for kidney prognosis has recently been emphasized, but validated biomarkers for predicting histology are still lacking. The aim of our study was to evaluate different serum and …
#1287 Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode Open
Background and Aims Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is foundational in the management of chronic kidney disease (CKD) and heart failure (HF) but increases the risk of hyperkalaemia (HK). Current guidelines re…
View article: #1303 Hyperkalaemia-related RAASi reduction and estimated number needed to treat to avoid a first hospitalisation by maintaining RAASi
#1303 Hyperkalaemia-related RAASi reduction and estimated number needed to treat to avoid a first hospitalisation by maintaining RAASi Open
Background and Aims Guidelines recommend renin-angiotensin-aldosterone system inhibitor (RAASi) therapy at the maximum tolerated dose in patients with chronic kidney disease (CKD) and/or heart failure (HF). Hyperkalaemia (HK) may be a barr…
View article: #57 Tubular biomarkers in proteinuric kidney diseases
#57 Tubular biomarkers in proteinuric kidney diseases Open
Background and Aims Proteinuria is not only a biomarker of chronic kidney disease (CKD) and a risk predictor of adverse outcomes but also a driver of kidney disease progression. The excessive filtration of plasma proteins through the glome…
View article: Tubular biomarkers in proteinuric kidney disease: histology correlation and kidney prognosis of tubular biomarkers
Tubular biomarkers in proteinuric kidney disease: histology correlation and kidney prognosis of tubular biomarkers Open
Background Proteinuria is not only a biomarker of chronic kidney disease (CKD) but also a driver of CKD progression. The aim of this study was to evaluate serum and urinary tubular biomarkers in patients with biopsied proteinuric kidney di…
#217 Renin-angiotensin-aldosterone system blockers effect in CKD progression in hypertensive elderly patients without proteinuria: PROERCAN trial Open
Background and Aims Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers …
View article: Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis Open
Background The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. Methods This is a retrospective, observational…
The Moderating Role of Health Variables on the Association between Physical Exercise and Quality of Life in Patients with End-Stage Renal Disease Open
Scientific evidence demonstrates the positive impact that physical exercise has on the quality of life (QOL) of patients with chronic kidney disease (CKD). However, no study has proposed a model investigating the effect physical exercise h…
Diagnosis and Management of Malnutrition in Patients with Heart Failure Open
Heart failure is a disease with an increasingly greater prevalence due to the aging population, the development of new drugs, and the organization of healthcare processes. Malnutrition has been identified as a poor prognostic factor in the…
Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study Open
Atrial fibrillation (AF) is the most common arrhythmia in patients with chronic kidney disease (CKD), and its presence is associated with a higher risk of stroke and mortality. Material and Methods: The FAERC study performed a retrospectiv…
View article: Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future
Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future Open
Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis …
Improving LSTMs’ under-performance in Authorship Attribution for short texts Open
© ACM 2022. This is the author's version of the work. It is posted here for your personal use. Not for redistribution. The definitive Version of Record was published in EICC '22: Proceedings of the 2022 European Interdisciplinary Cybersecu…
Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum Open
Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the…
View article: Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA
Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA Open
Background Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months …
Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study Open
Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect o…
View article: COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study Open
Background Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about kidney replacement therapy (KRT) s…
View article: Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis
Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis Open
Background Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined…
Erratum to: COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Open
In the originally published version of this article, the ERACODA collaborators were incorrectly listed. The names and affiliations of these Collaborating authors, and the number of records entered in the ERACODA database have now beenmoved…
View article: COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Open
Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient popu…
FP052CLINICAL REAL EXPERIENCE OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCSTIC DISEASE TREATED WITH TOLVAPTAN Open
Scale (PDS).Other measurements include general HRQoL using the Short Form Health Survey v2 (SF-12), treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM-9), and treatment preferences using a discrete c…